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Abstract Alzheimer’s disease (AD) is a neurode-
generative disorder presenting one of the biggest
healthcare challenges in developed countries. No
effective treatment exists. In recent years the main
focus of AD research has been on the amyloid
hypothesis, which postulates that extracellular precip-
itates of beta amyloid (Ab) derived from amyloid
precursor protein (APP) are responsible for the
cognitive impairment seen in AD. Treatment
strategies have been to reduce Ab production through
inhibition of enzymes responsible for its formation, or
to promote resolution of existing cerebral Ab plaques.
However, these approaches have failed to demonstrate
significant cognitive improvements. Intracellular
rather than extracellular events may be fundamental
in AD pathogenesis. Selenate is a potent inhibitor of
tau hyperphosphorylation, a critical step in the
formation of neurofibrillary tangles. Some selenium
(Se) compounds e.g. selenoprotein P also appear to
protect APP against excessive copper and iron
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deposition. Selenoproteins show anti-inflammatory
properties, and protect microtubules in the neuronal
cytoskeleton. Optimal function of these selenoenzymes
requires higher Se intake than what is common in
Europe and also higher intake than traditionally
recommended. Supplementary treatment with
N-acetylcysteine increases levels of the antioxidative
cofactor glutathione and can mediate adjuvant protec-
tion. The present review discusses the role of Se in AD
treatment and suggests strategies for AD prevention by
optimizing selenium intake, in accordance with the
metal dysregulation hypothesis. This includes in par-
ticular secondary prevention by selenium supplemen-
tation to elderly with mild cognitive impairment.
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Introduction
Alzheimer’s disease (AD) is a neurodegenerative dis-
order prevalent in old age. In developed countries 13 %
of people over 65 suffer from AD according to the
Alzheimer’s Association. Projected AD prevalence
indicate 100 million patients globally by 2050 (Alzhei-
mer’s 2015), leading to considerable economic burden
for society and suffering for patients and caregivers. AD
is classified as genetic or sporadic. Genetic AD is an
early-onset hereditary disease representing 1–2 % of
diagnosed cases (Campion et al. 1999). In genetic AD
mutated genes coding for amyloid precursor protein
(APP; chromosome 21) are found, and presenilin 1
(PS1; chromosome 14) and presenilin 2 (PS2; chromo-
some 1), promote amyloid beta (Ab) formation. The
vast majority of patients suffer from sporadic AD.
Many sporadic AD patients are carriers of the e4
allele of the ApoE gene (apolipoprotein E; chromo-
some 19). The mechanism whereby ApoE e4 allele
increases AD risk is largely unknown (Hardy and
Selkoe 2002). Recent research has unmasked minor
mutations which mediate an intermediate AD risk.
Most genes associated with AD roughly cluster within
three metabolic pathways: lipid metabolism, inflam-
matory response, and endocytosis (Giri et al. 2016).
Aging is considered the principal risk factor for
sporadic AD, followed by hypertension, dyslipidemia,
metabolic syndrome and diabetes (Drachman 2014).
In the present paper, we first discuss treatment
strategies based on traditional hypotheses of AD
pathogenesis: (a) the transmitter hypothesis, (b) the
metabolic hypothesis, (c) the tau protein hypothesis,
and (d) the amyloid cascade hypothesis. Then we
address the metal-based hypothesis of neuroinflam-
mation which opens new therapeutic possibilities
(Ward et al. 2014). Oxidative stress from copper
(Cu) and iron (Fe) toxicity is implicated in the metal
hypothesis of AD pathogenesis. In this context we
discuss a putative therapeutic or preventive role of
selenium (Se) supplementation, evoked by a Swedish
study reporting improved vitality and reduced signs of
inflammation and oxidative stress after Se yeast and
coenzyme Q10 intervention in an elderly population
(Alehagen et al. 2013).
Traditional hypotheses
The transmitter hypothesis
Cholinergic neurons projecting to the hippocampus in
the temporal lobe are affected early in AD. Deficient
spatial memory in rodents has been mapped to grid
cells that collect sensory signals in the entorhinal
cortex (Hafting et al. 2005). The language problems
and declining verbal recall characterizing AD patients
are presumed to arise from dysfunction in hippocam-
pal regions (Lim et al. 2012), and these cells are
influenced by cholinergic modulation (Konishi et al.
2015). Loss of cholinergic inputs to the hippocampus
is a well characterized abnormality in AD. Decreased
acetylcholine release combined with reductions in
nicotinic and muscarinic receptors in the cortex and
hippocampus of AD brains examined post-mortem has
been seen (Tata et al. 2014). Acetylcholinesterase
inhibitors used in AD treatment act by increasing
acetylcholine bioavailability at synaptic loci. Unfor-
tunately, these enzyme inhibitors are not capable of
reversing AD, nor slowing disease progression (Wal-
lace and Bertrand 2013). Memantine acts on the
N-methyl-D-aspartate (NMDA) receptors blocking
glutamate activity (Parsons et al. 2007). A dysfunction
of glutamatergic transmission has been hypothesized
to be involved in the neurodegeneration in AD.
Memantine appears to improve this dysfunction, and
has been associated with a moderate decrease in
clinical deterioration, with a small positive effect on
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cognition (Areosa et al. 2005). However, although
transmitter dysfunction is seen in AD, it can be
suspected that the initial biochemical lesions involve
structural and functional impairment of vital proteins
responsible for transmitter transport and neuronal
integrity.
The metabolic hypothesis
Clinical studies suggest that the metabolic syndrome,
including hypertension, obesity, and insulin resistance
or type 2 diabetes (T2DM), is a significant risk factor
for AD development (Kivipelto et al. 2005). Disturbed
hippocampal insulin signalling is likely present in AD
(Hokama et al. 2014). Increased insulin resistance and
oxidative stress with elevated levels of advanced
glycation end products (AGE) are proposed mecha-
nisms by which metabolic syndrome may increase the
risk of AD (Li et al. 2012). A recent study in mice
indicated an association between amount of hypotha-
lamic beta-amyloid fragments, neuroinflammation
and peripheral glucose intolerance (Clarke et al.
2015). Reactive oxygen species (ROS) and tumor
necrosis factor alpha also contribute to this intriguing
syndrome combination (Lourenco et al. 2013). As the
molecular mechanisms in AD and in insulin resistance
seem related, it is tempting to assume that drugs used
for T2DM treatment e.g. the glitazones could be
protective also in AD. A phase II trial with rosiglita-
zone for 6 months reported improvements in memory
and attention in patients who did not possess an e4
allele of the ApoE gene (Risner et al. 2006), but a
phase III rosiglitazone trial failed (Gold et al. 2010).
However, insulin resistance is associated with
increased AGE formation, decreased protection
against oxygen radicals (Aaseth and Stoa-Birketvedt
2000) and raised levels of methylglyoxal (MGA)
(Thornalley et al. 1999). These substances are all
neurotoxic and possess high reactivity toward thiol
(SH) groups such as the numerous microtubule SH
groups in the neuronal cytoskeleton. Increased MGA
concentrations in cerebrospinal fluid have been
reported in AD (Kuhla et al. 2005), and may contribute
to tau disintegration and tangle formation.
The tau hyperphosphorylation hypothesis
Tau is a neuronal, microtubulus-associated protein,
which in healthy brains regulates microtubuli dynamics
(Yuraszeck et al. 2010). Derangements of microtubuli
and of the neuronal cytoskeleton provide clues to the
understanding of AD pathogenesis. Intact microtubuli
are involved in transport of essential substances from
neuronal bodies to synaptic structures. Phosphorylation
regulates tau protein binding to microtubuli. Under
physiological conditions the tau protein remains sol-
uble, but hyperphosphorylation compromises its normal
functions (Mehta et al. 2015), and leads to formation of
insoluble neurofibrillary tangles, which are bundles of
paired helical protein filaments. Such excessive phos-
phorylation in AD must result from an imbalance
between phosphorylating kinases and de-phosphorylat-
ing phosphatases. Increased expression of active
kinases adjacent to neurofibrillary tangles has been
described in AD (Hochgrafe et al. 2015). One of these
kinases and a potential drug target is cyclin-dependent
kinase 5 (CDK5). Increased intracellular calcium in AD
brains is associated with CDK5 activation (Shukla et al.
2012). CDK5 inhibitors have demonstrated neuropro-
tective properties in in vitro and in vivo AD models
(Zimmer et al. 2012). Sodium selenate also reduces tau
phosphorylation, both in cell cultures and in AD mouse
models (Corcoran et al. 2010b). Administration of
selenate to rodents produces cognitive improvements
and reduced neurodegeneration (van Eersel et al. 2010).
In these models selenate is presumably converted to
specific selenoproteins including glutathione peroxi-
dases (Fig. 1), which may attenuate the intracellular
burden of ROS and thereby protect microtubuli in the
cytoskeleton.
The amyloid cascade hypothesis
The amyloid precursor protein (APP) is a glycosylated
protein that is uniformly found in cell membranes,
most abundant in the brain. A hypothesis claims that
the membrane bound protein APP acts as a Cu
chaperone, thereby exerting cytoprotective functions
(Prohaska and Gybina 2004). Apparently, APP is
involved in synaptic repair and in cell signaling
(Priller et al. 2006). Substances synthesized in the cell
bodies of neurons must be transported outward to the
distal synapses. It has been found that APP can
mediate interactions that facilitate this transport
(Jonsson et al. 2012). A mutation in APP makes the
protein more resistant against degradation and protects
against cognitive decline (Jonsson 2013). APP is
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degraded into several peptides by the three intracel-
lular enzymes: a-, b-, and c-secretases. Soluble
cleavage products might also have cytoprotective
effects on synaptic structures. Several isoforms of the
Ab-peptide degradation product exist (Mawuenyega
et al. 2013). In dominant genetic forms of AD, the
disease is thought to be due to over production of Ab,
or an increase in Ab42 to Ab40 ratio (Kumar-Singh
et al. 2006). The Ab-peptide with 42 amino acids, Ab
(1–42), usually called Ab, is an insoluble variant that
is prevalent in both sporadic and genetic AD, and
constitutes the amyloid core in the precipitated
plaques (Gaggelli et al. 2006).
Active immunization (vaccination) with either Ab
(1–42) or smaller Ab fragments has been evaluated
in transgenic mouse models of AD. Such vaccina-
tion will generally activate the phagocytotic capacity
of microglia. The early human tests using a full-
length Ab with an added adjuvant resulted in serious
adverse events including aseptic meningoencephali-
tis (Gilman et al. 2005). Later vaccines were
composed from a shorter Ab fragment in an attempt
to avoid side effects. A vaccine denoted CAD106
has reached the clinical phases of development
(Wiessner et al. 2011), showing specific antibody
response in a majority of treated patients without
serious adverse reactions, but without significant
therapeutic effect. Other vaccines are in preclinical
stages (Panza et al. 2014).
Passive immunization involves i.v. administration
of antibodies directed specifically against Ab. Studies
in transgenic animals have shown that passive immu-
nization reduces cerebral amyloid load. Bap-
ineuzumab and solanezumab are monoclonal
antibodies against Ab fragments (Tayeb et al. 2013).
Both drugs have reached advanced stages of clinical
development (Salloway et al. 2014), but without
producing significant clinical improvement in humans
(Tayeb et al. 2013). So far, immunotherapy has not
proven successful in arresting the cognitive decline in
AD patients. Since APP and its physiological degra-
dation products exert cytoprotective functions,
immunotherapy is not expected to become a treatment
of choice.
Fig. 1 Biotransformation of selenite and seleno-amino acids to
selenide, selenoproteins and excretable metabolites. The reduc-
tion of selenite is facilitated by GSH, glutaredoxins, glutathione
reductase and/or thioredoxin (Trx) and TrxR. It consumes
reducing equivalents, NADPH. Selenate that is transported into
cells by an anion transport mechanism (Jager et al. 2016), is also
reduced to selenide, but the intracellular reduction of selenate to
selenite is less efficient and not fully understood. Hydrogen
selenide (HSe-) and methyl selenide (MeSe-) react with
oxygen and thiols and complete the redox-cycle. Selenium can
be incorporated specifically into selenoproteins via pathways
from selenide and the synthesis of selenophosphate. Selenome-
thioneine can be converted to MeSe- or to selenocysteine via
the transsulfuration pathway or unspecifically replace its sulfur
analogue in proteins. Among excretory metabolites are seleno-
sugars and at high doses dimethylselenide and trimethyl
selenonium ion (TMSe?) (Alexander 2014)
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The neuroinflammation hypothesis
As discussed above, the insoluble APP derivative Ab
appears to be responsible for plaque formation
(Castello and Soriano 2014), and Ab may induce
oxidative stress and microinflammation. An early
hypothesis was that suppressing of inflammation could
arrest precipitation of Ab and cognitive decline. This
therapeutic exploration began with the observation
that several nonsteroidal anti-inflammatory drugs
(NSAIDs) decreased Ab levels in animal models.
Ibuprofen, sulindac and flurbiprofen were considered
as promising drugs (Du et al. 2014b). The mechanism
of action of NSAIDs was ascribed to their inhibition of
cyclooxygenases leading to reduced inflammation and
thus reduced Ab precipitation. Yet ibuprofen was
ineffective for AD treatment in clinical trials (Pasqua-
letti et al. 2009), and independent research has failed
to show positive results of treatment with NSAIDs in
AD. Interestingly however, some NSAIDs possess
copper-chelating properties (Puranik et al. 2016) and
further research on possible therapeutic effects of
selected NSAIDs in relation to the metal hypothesis of
neuroinflammation is justified. Also the key role of
microglia in neuroinflammatory processes deserves
further attention (Xiang et al. 2006). It has been found
that microglia surrounds Ab plaques (ElAli and Rivest
2016). Furthermore, it has been reported that Se
abrogates stress-induced microglial cell migration
(Dalla Puppa et al. 2007). Further research is neces-
sary to explore if Se attenuates the inflammatory
cascade associated with cognitive decline in AD.
The metal-based hypothesis of neuroinflammation
Copper and iron dysregulation in AD
It has been reported that Fe and Cu accumulate in AD
plaques, and this deposition appears to promote the
progression of the Ab cascade (Altamura and Muck-
enthaler 2009). Inside of neurons Fe and Cu binding to
hyperphosphorylated tau protein precede the forma-
tion of intracellular tangles (Barnham and Bush 2014).
The presence of free Fe(II) or Cu(I) species will induce
deleterious Fenton reactions with ROS generation and
microinflammation (Ward et al. 2015).
Experiments indicate that ceruloplasmin (CP), a Cu
containing enzyme with ferroxidase activity, protects
CNS from Fe(II)-mediated injury (Patel et al. 2002).
Torsdottir et al. (2011) found that the CP ferroxidase
activity was lower in mild cognitive impairment (MCI)
patients than in controls although CP concentrations
were similar in both groups (Torsdottir et al. 2011).
They explained the discrepancy by a deficient CP Cu
incorporation, while the synthesis of apo-CP was
unaffected. Brewer et al. (2010) found that CP activity
but not amount of CP was lower in AD patients than in
controls (Brewer et al. 2010). Here, it is pertinent to
recapitulate clinical and neuropathological findings in
aceruloplasminemia, a rare hereditary disorder caused
by mutation in the CP gene and characterized by absent
serum CP activity with Fe deposition in the brain
leading to neuropsychiatric symptoms (Kono 2013).
Although aceruloplasminemia patients presented five
to ten times higher brain tissue Fe concentrations than
controls (Morita et al. 1995), no brain amyloid or tau
protein precipitation was seen (Gonzalez-Cuyar et al.
2008; Kaneko et al. 2012). Cognitive symptoms in
aceruloplasminemia patients include executive dys-
function suggesting fronto-striatal involvement, rather
than hippocampal impairment (Kono 2013).
Sparks and Schreurs (2003) reported that minor
(0.12 mg/L) Cu excess in drinking water together with
cholesterol in the chow for 10 weeks accelerated the
formation of amyloid deposits around cerebral vessels
and induced learning deficits in a rabbit model (Sparks
and Schreurs 2003). Subsequently, Squitti et al. (2011)
argued that the level of free serum Cu in AD patients
has a predictive value in assessing disease progression
(Squitti et al. 2011). When discussing the Cu hypoth-
esis for AD, some characteristics of Wilson disease
(WD) may be relevant (Brewer et al. 2010). In WD, Cu
levels in the brain are increased by a factor of 5–10
(Horoupian et al. 1988), but the characteristic AD
pathology is not present (Meenakshi-Sundaram et al.
2008). Cognitive testing in WD reveals deficit in the
executive domain rather than in episodic memory
(Iwanski et al. 2015). Together with the findings in
aceruloplasminemia, this absence of AD pathology in
WD brains suggests that an overall elevation of Cu and
Fe concentrations in CNS is not sufficient to initiate
Ab and tau precipitation. Thus, the initiation of Ab and
tau related pathology must be caused by other stimuli,
e.g. by long-term exposure to ROS or AGE, although
trapping of Cu and Fe may enhance the progression.
Surprisingly, the brains of AD patients are not
characterized by increased overall Cu concentrations
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(Exley et al. 2012; Schrag et al. 2011). However, a
hypothesis claims that Cu is removed from various
regions of the brain and trapped by Ab in the
pathological plaques. Consistent with this, Maynard
et al. (2002) reported that overexpression of the
carboxyl-terminal fragment of APP with copper-
binding Ab-fragment in a transgenic mouse model
resulted in a redistribution of Cu in the brain and
progression of amyloid precipitation (Maynard et al.
2002). Total Cu remains unchanged in serum or
cerebrum in AD patients when compared to healthy
subjects (Bucossi et al. 2011), but its intracerebral
distribution appears to be deranged.
Metal chelation as a therapeutic strategy
Dyshomeostasis of Cu and Fe in AD brains with
accumulation of these metals in plaques and tangles
may be accompanied by increased generation of ROS
and progression of tissue damage. An early study
showed that Fe chelation with deferoxamine (125 mg
i.m. twice daily/5 days/week for 24 months) resulted
in a significant reduction in the rate of decline of daily
living skills in 48 AD patients, but not in AD patients
receiving placebo (McLachlan et al. 1993). Since then,
only few chelating agents have been examined in
clinical trials for the treatment of AD, viz. clioquinol
(iodochlorhydroxyquin) and PBT2 (5,7-dichloro-2-
(dimethylamino)-methyl)-8-hydroxyquinoline). Both
agents bind local excesses of Cu and Fe in the brain,
thereby presumably retarding the amyloid plaque
progression (Bush 2002; Lannfelt et al. 2008; Ritchie
et al. 2003). Although none of these studies showed
clear clinical effect of chelation therapy in AD, post
hoc analyses appeared promising (Barnham and Bush
2014; Faux et al. 2010), and indicated that the
hydroxyquinoline derivatives act as chaperone-
mimetic agents (Ayton et al. 2015). However, long-
term use of hydroxyquinolines may give rise to serious
side effects, and the search for less toxic agents is
encouraged (Meade 1975).
Selenium as a protective and chelating agent
Selenium is a trace element crucial to cerebral functions.
During Se depletion brain Se is maintained at the
expense of other tissues whereas severe Se deficiency
causes irreversible brain injury (Burk and Hill 2009).
The circulating Se transporter, selenoprotein P (SEPP),
appears to have a special role in the delivery of Se to the
brain and neurons by entering via the multifunctional
apolipoprotein E receptor 2 (ApoER2), a member of the
lipoprotein-receptor family that is expressed in neurons
in the brain (Burk et al. 2014). In the brain SEPP is
primarily provided by synthesis in the astroglial cells.
Mice without the machinery for SEPP synthesis under
Se deficient conditions develop spasticity, abnormal
movements, and seizures (Schweizer et al. 2004). While
SEPP is the important extracellular selenoprotein,
glutathione peroxidases (GPx1 acting on soluble
cytosolic peroxides and GPx4 acting on membrane
bound phospholipid peroxides) are important intracel-
lular antioxidants in neurons and glia (Mitozo et al.
2011; Zhang et al. 2010). Also thioredoxin reductases
are abundantly expressed in neurons and glia (Godoy
et al. 2011). These selenoproteins contain Se in the form
of amino acid selenocysteine (SeCys) which differs
from cysteine by a single atom (Se vs. S), conferring a
lower pKa (5.2 vs. 8.3) and higher reactivity to its
functional selenol group. GPx contains only one SeCys
residue, whereas SEPP contains 10 SeCys residues
conferring a high chelator affinity to Cu(I) (Aaseth et al.
2016). In vitro SEPP has been shown to inhibit Cu
induced Ab aggregation (Du et al. 2014b).
Evidence from human studies suggests a role for Se
and selenoproteins in protection against cognitive
decline. In the InCHIANTI cohort study of 1012 Italian
participants aged 65 years or older, 59 performance-
based assessment scores of coordination as well as the
MMSE-score were significantly reduced in partici-
pants with low plasma Se (\66.7 lg/L) compared to
those with higher ([82.3 lg/L) concentrations (Shahar
et al. 2010). In the French EVA cohort of 1166 people
aged 60–70 years (Berr et al. 2000) a 58 % increased
odds ratio of cognitive decline was recorded over four
years in participants with a Se concentration in the 1st
quartile (\75.8 lg/L) at baseline, as compared to a
mean baseline plasma Se level of 86.9 lg/L. Further-
more, cognitive decline was significantly associated
with the magnitude of plasma Se decrease over nine
years, which attained a decrease of 0.35 lg/L in one of
the subgroups (Akbaraly et al. 2007). In a cross-
sectional survey of 2000 rural Chinese adults aged
65 years or older, low nail Se concentration was
significantly associated with low cognitive scores in
four of five tests, with a dose-response effect across Se
quintiles (Gao et al. 2007). From Spain Gonzalez-
Domınguez et al. (2014) in a cross sectional study
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found lower Se levels in serum from AD patients
(121 lg/L) in comparison to elderly MCI subjects
(127 lg/L) (Gonzalez-Dominguez et al. 2014). Also in
patients with very mild AD (MMSE score[ 20) Se
levels in plasma were reported to be lower (82.2 vs.
93.2 lg/L) compared to healthy age-matched elderly
subjects in a Dutch cross-sectional study (Olde Rikkert
et al. 2014).
In several European countries the daily Se intake is
too low to obtain optimal function of important
selenoenzymes (Fig. 2). The European data on
increased cognitive decline at low Se status are in
agreement with cross-sectional studies from Brazil
and Turkey (Cardoso et al. 2010; Vural et al. 2010).
On the other hand a study from India did not find low
Se concentrations (174 vs. 188 lg/kg) in patients with
AD compared with healthy controls, but their Se levels
were higher than the European levels (Krishnan and
Rani 2014). Supplementation with compounds con-
taining Se has shown potential for stimulating cogni-
tive improvement (Kesse-Guyot et al. 2011; Scheltens
et al. 2010). Cardoso et al. (2015) reported that the
daily supplement with one Brazilian nut, correspond-
ing to about 280 lg Se/day, over 6 months was
associated with cognitive performance improvement
when given to patients with mild cognitive impairment
(Cardoso et al. 2015).
Animal models and in vitro Se studies are in
accordance with the observations from human sur-
veys. Sodium selenate treatment reduced tau phos-
phorylation, by activation of protein phosphatase 2A
(PP2A), both in cell cultures and tau transgenic animal
models (Corcoran et al. 2010b; van Eersel et al. 2010).
This treatment prevented and reversed memory and
motor deficits; neurofibrillary tangles formation and
neurodegeneration in transgenic animals (Ishrat et al.
2009; van Eersel et al. 2010) at a dose of 1 mg/kg bw
selenate (van Eersel et al. 2010). Treatment of
transgenic AD mice with selenomethionine resulted
in reduced total and phosphorylated tau, lower
inflammatory biomarkers and improvement in cogni-
tion (Song et al. 2014).
A hypothesis for protection by selenoproteins
High extracellular SEPP levels of have been found in
the brain (Bellinger et al. 2008; Steinbrenner and Sies
2013; Takemoto et al. 2010). All regions of mouse
Fig. 2 Average daily selenium intake in various countries.
Data are from Birgisdottir et al. (2013), Ellingsen et al. (2009),
Fairweather-Tait et al. (2011), Vanderlelie and Perkins (2011);
Rayman (2005), Maihara et al. (2004), Stoffaneller and Morse
(2015). Because of import of wheat, Norway is slightly higher in
Se intake than Denmark and Sweden. Optimization of seleno-
protein P requires a daily intake of about 105 lg (Hurst et al.
2010), indicated by a dotted line
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brain appear to be dependent on SEPP for maintenance
of proper functions (Nakayama et al. 2007). Knock-
out of SEPP or ApoER2 in mice resulted in neurolog-
ical dysfunction, particularly when fed a low Se diet,
and it appears that under low Se supply these two
proteins are necessary to maintain Se in the brain and
prevent neuron degeneration (Burk et al. 2014; Caito
et al. 2011; Steinbrenner and Sies 2013; Valentine
et al. 2008). Regional progression of neurodegenera-
tion in the brain of the SEPP knock-out mice has been
studied in order to map neuronal cell death, and
evaluate neuronal structural changes within the hip-
pocampus (Caito et al. 2011). Neurodegeneration was
found to be present in all studied brain regions in the
knock-out animals fed the Se-deficient diet (Caito
et al. 2011). The neurodegeneration was predomi-
nantly axonal, however neuronal bodies in the
somatosensory cortex and lateral striatum appeared
also to be severely deteriorated. Morphological anal-
ysis of the hippocampus revealed decreased dendritic
length, density and functionally. A defect in the long
term potentiation of the hippocampus, essential for
memory imprinting, was also noted. These findings are
in line with the hypothesis that Se deficiency con-
tributes to functional deficits seen in AD (Caito et al.
2011; Peters et al. 2006).
The expression of SEPP in postmortem tissue from
individuals with the hallmark lesions of AD and
individuals without these lesions has been examined
(Bellinger et al. 2008). SEPP immunoreactivity was
co-localized with Ab plaques and neurofibrillary
tangles (Bellinger et al. 2008). These observations
suggest some form of interaction between SEPP and
Ab, leading to complex formation. Like SEPP, Ab is
also a strong metal chelator, binding for instance Cu
(2016; Ma et al. 2006; Myhre et al. 2013; Syme et al.
2004), and Fe (Myhre et al. 2013). Ternary complexes
can be formed between metal cations, Ab and SEPP
and such complexes are presumably less toxic than
Ab-metal complexes alone. Since Cu is one of the
metals abundant in Ab (Myhre et al. 2013) and Cu(I)
binds very strongly to Se atoms, a ternary complex
between Cu(I), Ab and SEPP can explain the co-
localization of SEPP with Ab in AD (Aaseth et al.
2016). SEPP also contains two His-rich regions that
contribute to its affinity for Cu and Fe.
Thus SEPP chelation blocks metal-mediated Ab-
aggregation and ROS generation [110]. The trapping
of SEPP by Ab-plaques may reduce its availability for
the synthesis of intracellular selenoproteins including
thioredoxin reductase (TrxR) and GPx. Together with
glutathione (GSH) these intra-neuronal selenoen-
zymes operate as intracellular antioxidants, thereby
inhibiting tau aggregation (Du et al. 2014a). Selenium
treatment has been reported to reduce tau phosphory-
lation in transgenic rats (Yim et al. 2009). In healthy
brains the microtubule-associated tau protein regu-
lates microtubule dynamics (Yuraszeck et al. 2010).
The exact role of GPx and its cofactor GSH for
protection of microtubules has yet not been fully
elucidated. It should be emphasized here that micro-
tubules are essential parts of the cytoskeleton, thereby
maintaining the three-dimensional structure of the
neurons. Microtubules play crucial roles in a variety of
cellular events, including axonal and dendritic trans-
port and neuronal growth and differentiation (Lasek
1981). Each tubulin monomer has at least 13 free SH
groups, and it presumably needs protection against
oxidative derangement by the GPx-GSH-system
(Fig. 3). The intracellular protector GSH (reduced
form) can be optimized by N-acetylcysteine supple-
mentation. A study on AD patients supplemented with
N-acetylcysteine over a six month period reported
improved performance on memory tests (Adair et al.
2001).
Apparently, optimal function of GPx and SEPP is
necessary for protection against the cognitive decline
characterizing AD. Optimal function requires higher
intakes of Se than officially recommended in Nordic
and other European countries. Selenium intake in
Fig. 3 Intracellular detoxification by GPx and GSH. Toxic
peroxides (R–OOH) are reduced to non-toxic R–OH by the
action of the selenoenzymes glutathione peroxidases (A) in the
presence of adequate amounts of the co-factor GSH found
intracellularly, in contrast to the negligible GSH-levels found
extracellularly. GSH is oxidized to its disulphide GSSG in this
reaction. The reduced form GSH is regenerated by intracellular
glutathione reductase (B) in the presence of NADPH2. This
same co-factor, GSH, can also detoxify the compounds glyoxal
and methylglyoxal which are neurotoxic byproducts of glucose
metabolism, particularly in cases of insulin resistance. The latter
reaction requires the presence of the glyoxalase enzyme
system (Aaseth et al. 2016)
834 Biometals (2016) 29:827–839
123
North-America and some other regions of the world
are considerably higher than in Europe (Fig. 2), which
might contribute to inconsistencies in the clinical
evidence as to the role of Se supplementation (Du et al.
2016; Loef et al. 2011). Results from a Swedish study
published in 2015 indicated improved vitality and
overall score of health related quality-of-life as a result
of intervention with Se and coenzyme Q10 to an
elderly population with mean baseline plasma Se of
67 lg/L (Johansson et al. 2015). The same interven-
tion study also demonstrated a decreased inflamma-
tory activity as registered by the biomarkers sP-
selectin and hs-CRP (Alehagen et al. 2015). The Se
supplement dose in this latter study was 200 lg/day,
given as selenized yeast. Another intervention that is
in progress is the PREADVISE study carried out in the
same regions of America as the SELECT study. Thus,
the population under investigation has a baseline Se
intake that is substantially higher than European
intakes (Fig. 3). Participants included in PREADVISE
had reported memory complaints at inclusion. The
design was double-blind, placebo controlled and
randomized, transformed into an observational cohort
after discontinuation of supplementation in the
SELECT parent trial. PREADVISE participants were
assessed at 130 local clinical study sites in the United
States, Canada, and Puerto Rico during the controlled
trial phase, with a followed up by telephone from a
centralized location during the observational phase
(Kryscio et al. 2013). Unfortunately, results from this
American study cannot be generalized to European
populations with lower Se levels.
Concluding remarks
Accumulated evidence indicates that AD neuropathol-
ogy involves multiple biological pathways. The amy-
loid cascade hypothesis has dominated the field for
over 20 years, resulting in a large number of studies
with focus on approaches to inhibit formation of and
remove Ab from senile plaques. Yet these trials have
failed to demonstrate significant cognitive improve-
ments in patients. Thus novel pharmacotherapies
should not be limited to the postulate of the amyloid
cascade hypothesis alone, since events occurring
intracellularly may prove to be more important for
an understanding of the pathology of AD.
Selenate can act as potent inhibitor of tau hyper-
phosphorylation, presumably by optimizing the func-
tions of antioxidative selenoenzymes that protect the
neuronal cytoskeleton. Several nutritional and life-
style factors may be involved in AD progression and
prevention and the preventive roles of intracellular
selenoenzymes against derangement of microtubules
and neuronal integrity in the hippocampal area are
emphasized in this review. A prophylactic role of
optimized Se intake is suggested. Primary prevention
should aim at an adequate nutritional intake of Se
securing optimal expression of selenoproteins.
A secondary prevention trial using Se supplemen-
tation at higher doses, e.g. 200 lg/day, to overcome
extracellular Se trapping by Ab in the brain, is of
particular importance. Selenized yeast has been used
in several clinical trials, although selenate, the primary
species used in animal models, is also well tolerated
and passes the blood brain barrier (Corcoran et al.
2010a). The intervention should be directed towards
elderly with diagnosed MCI. in European regions with
low baseline Se intake (Fig. 2), i.e. in Sweden and
Norway.
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